<p>Eledon Pharmaceuticals（納斯達克代碼：ELDN - 獲取免費報告）預計將在 2026 年 5 月 13 日星期三市場開盤前發佈其 2026 年第一季度的財報。分析師預計 Eledon Pharmaceuticals 本季度每股收益為（$0.22）。鼓勵個人訪問公司即將發佈的 2026 年第一季度財報概覽頁面，以獲取關於定於 2026 年 5 月 12 日星期二東部時間下午 4:00 的電話會議的最新詳情。</p>
<p>獲取 <strong>Eledon Pharmaceuticals</strong> 的提醒：</p>
<p>Eledon Pharmaceuticals（納斯達克代碼：ELDN - 獲取免費報告）上一次發佈財報是在 3 月 19 日星期四。該公司報告本季度每股收益（EPS）為（$0.10），超出市場共識預期的（$0.20）$0.10。</p>
<h2>Eledon Pharmaceuticals 股票表現</h2>
<p>納斯達克 ELDN 週三開盤價為 $3.78。該公司的 50 日移動平均線為 $3.06，200 日移動平均線為 $2.48。Eledon Pharmaceuticals 的 12 個月低點為 $1.35，12 個月高點為 $4.60。該股票的市值為 $2.8672 億，市盈率為 -7.27，貝塔值為 0.94。</p>
<h2>華爾街分析師預測增長</h2>
<p>另外，Weiss Ratings 在 3 月 27 日星期五的研究報告中重申了對 Eledon Pharmaceuticals 股票的 “賣出（d-）” 評級。三位分析師給予該股票買入評級，一位給予持有評級，一位給予賣出評級。根據 MarketBeat 的數據，該公司的共識評級為 “持有”，共識目標價為 $9.67。</p>
<p><strong>查看我們最新的 ELDN 股票報告</strong></p>
<h2>機構投資者對 Eledon Pharmaceuticals 的看法</h2>
<p>幾家機構投資者最近調整了對 ELDN 的持股。法國巴黎銀行金融市場在第三季度增持了 Eledon Pharmaceuticals 的股份，增幅為 143.7%。法國巴黎銀行金融市場目前擁有該公司 12,154 股股票，價值$31,000，此前在上個季度增持了 7,166 股。Millennium Management LLC 在第四季度購買了 Eledon Pharmaceuticals 的新股份，價值約為$36,000。Virtu Financial LLC 在第四季度購買了 Eledon Pharmaceuticals 的新股份，價值約為$39,000。Cetera Investment Advisers 在第四季度增持了 Eledon Pharmaceuticals 的股份，增幅為 72.9%。Cetera Investment Advisers 目前擁有該公司 26,584 股股票，價值$40,000，此前在上個季度增持了 11,207 股。最後，Marshall Wace LLP 在第四季度購買了 Eledon Pharmaceuticals 的新股份，價值約為$45,000。對沖基金和其他機構投資者持有該公司 56.77% 的股票。</p>
<h2>Eledon Pharmaceuticals 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Eledon Pharmaceuticals, Inc 納斯達克：ELDN 是一家臨牀階段的生物製藥公司，專注於發現和開發針對平滑肌功能障礙疾病的治療方案。該公司利用專有的離子通道調節平台，識別和優化小分子化合物，以恢復或抑制平滑肌活動，旨在解決胃腸、肝臟和心血管疾病。</p>
<p>Eledon 的產品管線包括多個針對高未滿足需求指徵的臨牀前和早期臨牀項目。</p>
<h2>特色文章</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Eledon Pharmaceuticals</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RUxETg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RUxETg"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Eledon Pharmaceuticals 嗎？</h2>
<p>在你考慮 Eledon Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Eledon Pharmaceuticals 並不在名單上。</p>
<p>雖然 Eledon Pharmaceuticals 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

ELDN

<p>Eledon Pharmaceuticals (NASDAQ:ELDN) 將於 5 月 13 日公佈 2026 年第一季度財報，分析師預測每股虧損 0.22 美元。該公司在 2025 年第四季度報告的每股虧損為 0.10 美元，超出預期。ELDN 股票開盤價為 3.78 美元，市值為 2.8672 億美元。分析師的評級意見不一，普遍評級為 “持有”，目標價為 9.67 美元。機構投資者持有該股票的 56.77%，公司專注於平滑肌功能障礙的治療</p>

<p>Eledon Pharmaceuticals (NASDAQ:ELDN - Get Free Report) is expected to be posting its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect Eledon Pharmaceuticals to post earnings of ($0.22) per share for the quarter. Individuals are encouraged to explore the company's upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 4:00 PM ET.</p>
<div class="lb-trans"><p>Eledon Pharmaceuticals（納斯達克代碼：ELDN - 獲取免費報告）預計將在 2026 年 5 月 13 日星期三市場開盤前發佈其 2026 年第一季度的財報。分析師預計 Eledon Pharmaceuticals 本季度每股收益為（$0.22）。鼓勵個人訪問公司即將發佈的 2026 年第一季度財報概覽頁面，以獲取關於定於 2026 年 5 月 12 日星期二東部時間下午 4:00 的電話會議的最新詳情。</p>
</div><p>Get <strong>Eledon Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Eledon Pharmaceuticals</strong> 的提醒：</p>
</div><p>Eledon Pharmaceuticals (NASDAQ:ELDN - Get Free Report) last released its earnings results on Thursday, March 19th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.10.</p>
<div class="lb-trans"><p>Eledon Pharmaceuticals（納斯達克代碼：ELDN - 獲取免費報告）上一次發佈財報是在 3 月 19 日星期四。該公司報告本季度每股收益（EPS）為（$0.10），超出市場共識預期的（$0.20）$0.10。</p>
</div><h2>Eledon Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Eledon Pharmaceuticals 股票表現</h2>
</div><p>NASDAQ ELDN opened at $3.78 on Wednesday. The business's 50 day moving average is $3.06 and its two-hundred day moving average is $2.48. Eledon Pharmaceuticals has a 12-month low of $1.35 and a 12-month high of $4.60. The stock has a market capitalization of $286.72 million, a price-to-earnings ratio of -7.27 and a beta of 0.94.</p>
<div class="lb-trans"><p>納斯達克 ELDN 週三開盤價為 $3.78。該公司的 50 日移動平均線為 $3.06，200 日移動平均線為 $2.48。Eledon Pharmaceuticals 的 12 個月低點為 $1.35，12 個月高點為 $4.60。該股票的市值為 $2.8672 億，市盈率為 -7.27，貝塔值為 0.94。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>Separately, Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Eledon Pharmaceuticals in a research report on Friday, March 27th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of &#34;Hold&#34; and a consensus price target of $9.67.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 3 月 27 日星期五的研究報告中重申了對 Eledon Pharmaceuticals 股票的 “賣出（d-）” 評級。三位分析師給予該股票買入評級，一位給予持有評級，一位給予賣出評級。根據 MarketBeat 的數據，該公司的共識評級為 “持有”，共識目標價為 $9.67。</p>
</div><p><strong>View Our Latest Stock Report on ELDN</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 ELDN 股票報告</strong></p>
</div><h2>Institutional Investors Weigh In On Eledon Pharmaceuticals</h2>
<div class="lb-trans"><h2>機構投資者對 Eledon Pharmaceuticals 的看法</h2>
</div><p>Several institutional investors have recently modified their holdings of ELDN. BNP Paribas Financial Markets boosted its stake in shares of Eledon Pharmaceuticals by 143.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 12,154 shares of the company's stock worth $31,000 after acquiring an additional 7,166 shares in the last quarter. Millennium Management LLC purchased a new stake in shares of Eledon Pharmaceuticals during the 4th quarter worth approximately $36,000. Virtu Financial LLC purchased a new stake in shares of Eledon Pharmaceuticals during the 4th quarter worth approximately $39,000. Cetera Investment Advisers boosted its stake in shares of Eledon Pharmaceuticals by 72.9% during the 4th quarter. Cetera Investment Advisers now owns 26,584 shares of the company's stock worth $40,000 after acquiring an additional 11,207 shares in the last quarter. Finally, Marshall Wace LLP purchased a new stake in shares of Eledon Pharmaceuticals during the 4th quarter worth approximately $45,000. Hedge funds and other institutional investors own 56.77% of the company's stock.</p>
<div class="lb-trans"><p>幾家機構投資者最近調整了對 ELDN 的持股。法國巴黎銀行金融市場在第三季度增持了 Eledon Pharmaceuticals 的股份，增幅為 143.7%。法國巴黎銀行金融市場目前擁有該公司 12,154 股股票，價值$31,000，此前在上個季度增持了 7,166 股。Millennium Management LLC 在第四季度購買了 Eledon Pharmaceuticals 的新股份，價值約為$36,000。Virtu Financial LLC 在第四季度購買了 Eledon Pharmaceuticals 的新股份，價值約為$39,000。Cetera Investment Advisers 在第四季度增持了 Eledon Pharmaceuticals 的股份，增幅為 72.9%。Cetera Investment Advisers 目前擁有該公司 26,584 股股票，價值$40,000，此前在上個季度增持了 11,207 股。最後，Marshall Wace LLP 在第四季度購買了 Eledon Pharmaceuticals 的新股份，價值約為$45,000。對沖基金和其他機構投資者持有該公司 56.77% 的股票。</p>
</div><h2>Eledon Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Eledon Pharmaceuticals 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Eledon Pharmaceuticals, Inc NASDAQ: ELDN is a clinical-stage biopharmaceutical company focused on the discovery and development of therapies for diseases characterized by smooth muscle dysfunction. The company leverages a proprietary ion-channel modulation platform to identify and optimize small-molecule compounds that can either restore or inhibit smooth muscle activity, with the goal of addressing gastrointestinal, hepatic and cardiovascular disorders.</p>
<div class="lb-trans"><p>Eledon Pharmaceuticals, Inc 納斯達克：ELDN 是一家臨牀階段的生物製藥公司，專注於發現和開發針對平滑肌功能障礙疾病的治療方案。該公司利用專有的離子通道調節平台，識別和優化小分子化合物，以恢復或抑制平滑肌活動，旨在解決胃腸、肝臟和心血管疾病。</p>
</div><p>Eledon’s pipeline comprises several preclinical and early-phase clinical programs targeting high-unmet-need indications.</p>
<div class="lb-trans"><p>Eledon 的產品管線包括多個針對高未滿足需求指徵的臨牀前和早期臨牀項目。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than Eledon Pharmaceuticals</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Eledon Pharmaceuticals</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RUxETg" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=ELDN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Eledon Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Eledon Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Eledon Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Eledon Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eledon Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Eledon Pharmaceuticals 並不在名單上。</p>
</div><p>While Eledon Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Eledon Pharmaceuticals 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Eledon Pharmaceuticals (ELDN) 預計將在週三宣佈財報